#10

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. P66823US0	APPLICATION NO. 09/849,400
	APPLICANT(S) LIN et al.	
	FILING DATE 7 May 2001	GROUP 1624

364

OIPE JC98 MAR 0 8 2002 PATENT & TRADEMARK OFFICE

RECEIVED MAR 1 4 2002 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							☐Yes ☐ No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

EXAMINER'S INITIAL			Include Author, Title, Date, Pertinent, etc.
	AA	2	William T. BELLANY, "P-Glycoproteins and Multidrug Resistance", 1996, Annu. Rev. Pharmacol. Toxicol., 36:161-183. 1
	AB	2	Jeffrey D. CHULAY et al., "Plasmodium Falciparum: Assessment of in Vitro Growth by [^{3}H] Hypoxanthine Incorporation", (1983), Experimental Parasitology, 55:138-146. 2
	AC	2	James M. FORD et al., "Cellular and Biochemical Characterization of Thioxanthenes for Reversal of Multidrug Resistance in Human and Murine Cell Lines", (1990), Cancer Research, 50:1748-1756. 3
	AD	2	Samuel K. MARTIN et al., "Reversal of Chloroquine Resistance in Plasmodium Falciparum by Verapamil", (1987), Science, 235:899-901. 4
	AE	2	Wilbur K. MILHOUS et al., "In Vitro Strategies for Circumventing Antimalarial Drug Resistance", (1989), Malaria and the Red Cell, 2:61-72. 5
	AF	2	A.M.J. ODUOLA et al., "Reversal of Mefloquine Resistance with Penfluridol in Isolates of Plasmodium Falciparum from South-West Nigeria", (1993), Transactions of the Royal Society of Tropical Medicine and Hygene, 87:81-83. 6
	AG	2	H.L. PEARCE et al., "Essential Features of the P-Glycoprotein Pharmacophore as Defined by a Series of Reserpine Analogs that Modulate Multidrug Resistance", (1989), Proc. Natl. Acad. Sci. USA, 86:5128-5132. 7
	AH	2	John M. ZAMORA et al., "Physical-Chemical Properties Shared by Compounds that Modulate Multidrug Resistance in Human Leukemic Cells", (1988), Molecular Pharmacology, 33:454-462. 8

EXAMINER	7/11/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.